STOCK TITAN

Werewolf Therapeutics, Inc. - $HOWL STOCK NEWS

Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: $HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Werewolf Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Werewolf Therapeutics's position in the market.

Rhea-AI Summary
Werewolf Therapeutics, Inc. (HOWL) announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the Evercore ISI HealthCONx Conference. The company is known for developing conditionally activated therapeutics to stimulate the immune system for cancer treatment. The event will take place on November 29, 2023, in Miami, Florida, with a live webcast link available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) reported preliminary data from the WTX-124 monotherapy dose-escalation arm of the Phase 1/1b clinical trial, showing compelling early evidence of dose-dependent anti-tumor and biomarker activity. Safety data indicate WTX-124 is generally well tolerated, with additional interim data and recommended dose for expansion expected in the first half of 2024. The company also announced the addition of WTX-518, a novel conditionally activated IL-18 INDUKINE molecule, to its pipeline of preclinical development candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. announces preliminary first-in-human clinical data from its lead clinical program, WTX-124x2101. The data shows dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors. Safety data indicates the drug is well-tolerated with no severe side effects. The company plans to continue dose escalation and expects additional data in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.44%
Tags
Rhea-AI Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced that interim first-in-human clinical results from the Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting. The results show that WTX-124 was well-tolerated with no dose limiting toxicities at doses up to 6mg. The data support the potential of WTX-124 to deliver a potent IL-2 to the tumor microenvironment in patients with solid tumors with limited toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences clinical trial
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. announces abstracts accepted for poster presentations at SITC annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
conferences
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. to host virtual R&D Event on September 18, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
Rhea-AI Summary
Werewolf Therapeutics, Inc. announces participation in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
-
Rhea-AI Summary
Werewolf Therapeutics to present company overview at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.42%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.88%
Tags
Werewolf Therapeutics, Inc.

Nasdaq:HOWL

HOWL Rankings

HOWL Stock Data

259.22M
22.58M
6.76%
73.87%
1.1%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WATERTOWN

About HOWL

we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.